{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T08:24:10Z","timestamp":1787646250264,"version":"build-2736575974"},"reference-count":61,"publisher":"Portland Press Ltd.","issue":"9","license":[{"start":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T00:00:00Z","timestamp":1787616000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100015090","name":"Imam Abdulrahman Bin Faisal University","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/501100015090","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["portlandpress.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,9,16]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Ovarian cancer remains one of the deadliest gynecological malignancies, mainly due to its late diagnosis, biological heterogeneity, and frequent development of chemoresistance. Recent evidence indicates that epigenetic dysregulation including aberrant DNA methylation, histone modifications, chromatin remodeling, and non-coding RNA networks plays an important role in the initiation, progression, and therapeutic response of ovarian cancer. Unlike genetic alterations, epigenetic modifications are reversible, making them attractive targets for drug development and precision oncology. In this review, we provide a detailed overview of the epigenetic mechanisms that control ovarian cancer biology, with specific focus on their role in drug resistance and disease recurrence. We discuss the role of epigenetic plasticity in enabling transition of tumor cells into drug tolerant, stem like phenotypes, leading to minimal residual disease and eventual relapse without permanent genetic changes. Attention is given to the influence of DNA methyltransferases, histone deacetylases, enhancer of zeste homolog 2, and chromatin remodeling complexes in the maintenance of adaptive resistance programs. We also discuss the evolving paradigm of epigenetic regulation, immune modulation and viral mimicry and provide the rationale for combining epigenetic therapies with immunotherapy and poly(ADP-ribose) polymerase inhibition. The article also reviews the results of recent clinical trials and evaluate the most recent advances in biomarker development, such as circulating DNA methylation signatures, microRNAs, and artificial intelligence-based liquid biopsy platforms. Finally, we discussed the potential implications of applying epigenetic profiling in the clinic for improved patient stratification and the potential for real-time monitoring of chemoresistance. These progresses make epigenetic regulation a promising strategy to overcome chemoresistance and improve personalized medicine of ovarian cancer.<\/jats:p>","DOI":"10.1042\/bsr20250409","type":"journal-article","created":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T07:24:41Z","timestamp":1787642681000},"update-policy":"https:\/\/doi.org\/10.1042\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Epigenetic mechanisms and clinical translation in ovarian cancer: from molecular pathways to precision therapy"],"prefix":"10.1042","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0068-5516","authenticated-orcid":false,"given":"Khaldoon","family":"Alsamman","sequence":"first","affiliation":[{"name":"Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"288","published-online":{"date-parts":[[2026,8,25]]},"reference":[{"key":"2026082503243536800_B1","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s12943-024-01967-3","article-title":"Drug resistance in ovarian cancer: from mechanism to clinical trial","volume":"23","author":"Wang","year":"2024","journal-title":"Mol. Cancer"},{"key":"2026082503243536800_B2","doi-asserted-by":"publisher","first-page":"5993","DOI":"10.3390\/cancers13235993","article-title":"Epigenetic mechanisms and therapeutic targets in chemoresistant high-grade serous ovarian cancer","volume":"13","author":"Matthews","year":"2021","journal-title":"Cancers (Basel)"},{"key":"2026082503243536800_B3","doi-asserted-by":"publisher","first-page":"4029","DOI":"10.3390\/cancers13164029","article-title":"Leveraging genomics, transcriptomics, and epigenomics to understand the biology and chemoresistance of ovarian cancer","volume":"13","author":"Mu\u00f1oz-Galv\u00e1n","year":"2021","journal-title":"Cancers (Basel)"},{"key":"2026082503243536800_B4","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.18632\/oncotarget.27246","article-title":"The prognostic role of microRNA in epithelial ovarian cancer: a systematic review of literature with an overall survival meta-analysis","volume":"11","author":"Ferreira","year":"2020","journal-title":"Oncotarget"},{"key":"2026082503243536800_B5","doi-asserted-by":"publisher","first-page":"863541","DOI":"10.3389\/fendo.2022.863541","article-title":"The emerging roles and therapeutic implications of epigenetic modifications in ovarian cancer","volume":"13","author":"Wang","year":"2022","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"2026082503243536800_B6","doi-asserted-by":"publisher","first-page":"1320185","DOI":"10.3389\/fgene.2023.1320185","article-title":"The role of circRNAs in regulation of drug resistance in ovarian cancer","volume":"14","author":"Zhan","year":"2023","journal-title":"Front Genet."},{"key":"2026082503243536800_B7","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.23758","article-title":"Clinical significance of promoter hypermethylation of genes in ovarian cancer","volume":"5","author":"Zhu","year":"2017","journal-title":"Oncotarget."},{"key":"2026082503243536800_B8","doi-asserted-by":"publisher","first-page":"1732","DOI":"10.1002\/ijc.33727","article-title":"Exploiting epigenetic dependencies in ovarian cancer therapy","volume":"149","author":"Coughlan","year":"2021","journal-title":"Int. J. Cancer"},{"key":"2026082503243536800_B9","doi-asserted-by":"publisher","first-page":"e9052","DOI":"10.7717\/peerj.9052","article-title":"EZH2\/H3K27Me3 and phosphorylated EZH2 predict chemotherapy response and prognosis in ovarian cancer","volume":"8","author":"Sun","year":"2020","journal-title":"PeerJ"},{"key":"2026082503243536800_B10","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/s13048-022-01012-1","article-title":"A comprehensive survey into the role of microRNAs in ovarian cancer chemoresistance; an updated overview","volume":"15","author":"Saburi","year":"2022","journal-title":"J. Ovarian Res."},{"key":"2026082503243536800_B11","doi-asserted-by":"publisher","first-page":"641937","DOI":"10.3389\/fimmu.2021.641937","article-title":"Double insurance for OC: miRNA-mediated platinum resistance and immune escape","volume":"12","author":"Zou","year":"2021","journal-title":"Front Immunol."},{"key":"2026082503243536800_B12","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1186\/s12935-021-02136-y","article-title":"Ovarian cancer: epigenetics, drug resistance, and progression","volume":"21","author":"Xie","year":"2021","journal-title":"Cancer Cell Int."},{"key":"2026082503243536800_B13","doi-asserted-by":"publisher","first-page":"e1235","DOI":"10.1002\/hsr2.1235","article-title":"The role of DNA methylation in ovarian cancer chemoresistance: a narrative review","volume":"6","author":"Song","year":"2023","journal-title":"Health Sci. Rep."},{"key":"2026082503243536800_B14","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1186\/s13048-021-00882-1","article-title":"MicroRNAs as the critical regulators of Cisplatin resistance in ovarian cancer cells","volume":"14","author":"Moghbeli","year":"2021","journal-title":"J. Ovarian Res."},{"key":"2026082503243536800_B15","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.3390\/cancers14061533","article-title":"Is there a role for epigenetic therapies in modulating DNA damage repair pathways to enhance chemotherapy and overcome drug resistance?","volume":"14","author":"Garner","year":"2022","journal-title":"Cancers (Basel)"},{"key":"2026082503243536800_B16","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.3390\/cancers12061607","article-title":"Overcoming platinum and PARP-inhibitor resistance in ovarian cancer","volume":"12","author":"McMullen","year":"2020","journal-title":"Cancers (Basel)"},{"key":"2026082503243536800_B17","doi-asserted-by":"publisher","first-page":"B091","DOI":"10.1158\/1535-7163.TARG-23-B091","article-title":"Abstract B091: overexpression of Muscleblind like splicing regulator 2 (MBNL2) enhances cisplatin resistance in ovarian cancer","volume":"22","author":"Ju","year":"2023","journal-title":"Mol. Cancer Ther."},{"key":"2026082503243536800_B18","doi-asserted-by":"publisher","first-page":"224","DOI":"10.5483\/BMBRep.2024-0167","article-title":"MBNL2 enhances cisplatin resistance by regulating apoptosis in ovarian cancer cells","volume":"58","author":"Sung","year":"2025","journal-title":"BMB Rep."},{"key":"2026082503243536800_B19","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1158\/1535-7163.MCT-17-0437","article-title":"Histone methyltransferase EZH2: a therapeutic target for ovarian cancer","volume":"17","author":"Jones","year":"2018","journal-title":"Mol. Cancer Ther."},{"key":"2026082503243536800_B20","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1038\/ncb3582","article-title":"ARID1A-mutated ovarian cancers depend on HDAC6 activity","volume":"19","author":"Bitler","year":"2017","journal-title":"Nat. Cell Biol."},{"key":"2026082503243536800_B21","doi-asserted-by":"publisher","first-page":"1057186","DOI":"10.3389\/fonc.2022.1057186","article-title":"Potential of histone deacetylase inhibitors for the therapy of ovarian cancer","volume":"12","author":"Guo","year":"2022","journal-title":"Front Oncol."},{"key":"2026082503243536800_B22","doi-asserted-by":"publisher","first-page":"4449","DOI":"10.3390\/cancers15184449","article-title":"MicroRNAs can influence ovarian cancer progression by dysregulating integrin activity","volume":"15","author":"Fasoulakis","year":"2023","journal-title":"Cancers (Basel)"},{"key":"2026082503243536800_B23","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.bcp.2019.01.009","article-title":"miR-142-5p enhances cisplatin-induced apoptosis in ovarian cancer cells by targeting multiple anti-apoptotic genes","volume":"161","author":"Li","year":"2019","journal-title":"Biochem. Pharmacol."},{"key":"2026082503243536800_B24","doi-asserted-by":"publisher","first-page":"693259","DOI":"10.3389\/fgene.2021.693259","article-title":"The emerging role of non-coding RNAs in drug resistance of ovarian cancer","volume":"12","author":"Lan","year":"2021","journal-title":"Front Genet."},{"key":"2026082503243536800_B25","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.3389\/fonc.2020.01084","article-title":"Roles of microRNAs in ovarian cancer tumorigenesis: two decades later, what have we learned?","volume":"10","author":"Alshamrani","year":"2020","journal-title":"Front Oncol."},{"key":"2026082503243536800_B26","doi-asserted-by":"publisher","first-page":"999174","DOI":"10.3389\/fcell.2022.999174","article-title":"Long noncoding RNAs as therapeutic targets to overcome chemoresistance in ovarian cancer","volume":"10","author":"Chen","year":"2022","journal-title":"Front Cell Dev. Biol."},{"key":"2026082503243536800_B27","doi-asserted-by":"publisher","first-page":"18625","DOI":"10.1038\/s41598-022-23149-1","article-title":"Precision gynecologic oncology: circulating cell free DNA epigenomic analysis, artificial intelligence and the accurate detection of ovarian cancer","volume":"12","author":"Bahado-Singh","year":"2022","journal-title":"Sci. Rep."},{"key":"2026082503243536800_B28","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1016\/j.ygyno.2022.03.018","article-title":"Methylated DNA markers for plasma detection of ovarian cancer: discovery, validation, and clinical feasibility","volume":"165","author":"Marinelli","year":"2022","journal-title":"Gynecol. Oncol."},{"key":"2026082503243536800_B29","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1038\/s42003-024-06909-9","article-title":"The chromatin landscape of high-grade serous ovarian cancer metastasis identifies regulatory drivers in post-chemotherapy residual tumour cells","volume":"7","author":"Croft","year":"2024","journal-title":"Commun. Biol."},{"key":"2026082503243536800_B30","first-page":"2025.2012.2004.692102","article-title":"A single-nucleus multimodal framework reveals epigenomic priming of chemoresistant states in ovarian cancer","author":"Landais","year":"2025","journal-title":"bioRxiv"},{"key":"2026082503243536800_B31","first-page":"271","article-title":"Resistance to cis- and carboplatin initiated by epigenetic changes in ovarian cancer patients","volume":"2","author":"Schwarzenbach","year":"2019","journal-title":"Cancer Drug Resist."},{"key":"2026082503243536800_B32","doi-asserted-by":"publisher","first-page":"3435","DOI":"10.1111\/cas.14599","article-title":"The clinical impact of intra- and extracellular miRNAs in ovarian cancer","volume":"111","author":"Yoshida","year":"2020","journal-title":"Cancer Sci."},{"key":"2026082503243536800_B33","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1158\/2159-8290.CD-12-0206","article-title":"MicroRNAs reprogram normal fibroblasts into cancer-associated fibroblasts in ovarian cancer","volume":"2","author":"Mitra","year":"2012","journal-title":"Cancer Discov."},{"key":"2026082503243536800_B34","doi-asserted-by":"publisher","first-page":"119801","DOI":"10.1016\/j.bbamcr.2024.119801","article-title":"Reprogramming of normal fibroblasts into ovarian cancer-associated fibroblasts via non-vesicular paracrine signaling induces an activated fibroblast phenotype","volume":"1871","author":"Axemaker","year":"2024","journal-title":"Biochim. Biophys. Acta Mol. Cell. Res."},{"key":"2026082503243536800_B35","doi-asserted-by":"publisher","first-page":"107701","DOI":"10.1016\/j.celrep.2020.107701","article-title":"Epigenetic reprogramming of cancer-associated fibroblasts deregulates glucose metabolism and facilitates progression of breast cancer","volume":"31","author":"Becker","year":"2020","journal-title":"Cell Rep."},{"key":"2026082503243536800_B36","doi-asserted-by":"publisher","first-page":"295","DOI":"10.3390\/cancers10090295","article-title":"Epigenetic crosstalk between the tumor microenvironment and ovarian cancer cells: a therapeutic road less traveled","volume":"10","author":"Klymenko","year":"2018","journal-title":"Cancers (Basel)"},{"key":"2026082503243536800_B37","doi-asserted-by":"publisher","first-page":"e004974","DOI":"10.1136\/jitc-2022-004974","article-title":"Inhibiting DNA methylation and RNA editing upregulates immunogenic RNA to transform the tumor microenvironment and prolong survival in ovarian cancer","volume":"10","author":"Gomez","year":"2022","journal-title":"J. Immunother Cancer"},{"key":"2026082503243536800_B38","doi-asserted-by":"publisher","first-page":"E10981","DOI":"10.1073\/pnas.1712514114","article-title":"Epigenetic therapy activates type I interferon signaling in murine ovarian cancer to reduce immunosuppression and tumor burden","volume":"114","author":"Stone","year":"2017","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"2026082503243536800_B39","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1016\/j.cell.2015.07.011","article-title":"Inhibiting DNA methylation causes an interferon response in cancer via dsRNA including endogenous retroviruses","volume":"162","author":"Chiappinelli","year":"2015","journal-title":"Cell"},{"key":"2026082503243536800_B40","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1016\/j.cell.2015.07.056","article-title":"DNA-demethylating agents target colorectal cancer cells by inducing viral mimicry by endogenous transcripts","volume":"162","author":"Roulois","year":"2015","journal-title":"Cell"},{"key":"2026082503243536800_B41","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1016\/j.ejca.2009.01.003","article-title":"The promises and pitfalls of epigenetic therapies in solid tumours","volume":"45","author":"Graham","year":"2009","journal-title":"Eur. J. Cancer"},{"key":"2026082503243536800_B42","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1080\/23808993.2019.1571906","article-title":"Emerging DNA methylation inhibitors for cancer therapy: challenges and prospects","volume":"4","author":"Gonzalez-Fierro","year":"2019","journal-title":"Expert Rev. Precision Med. Drug Development"},{"key":"2026082503243536800_B43","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s13148-018-0602-0","article-title":"Epigenetic therapy for ovarian cancer: promise and progress","volume":"11","author":"Moufarrij","year":"2019","journal-title":"Clin. Epigenetics"},{"key":"2026082503243536800_B44","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1158\/0008-5472.CAN-11-3909","article-title":"Epigenetic resensitization to platinum in ovarian cancer","volume":"72","author":"Matei","year":"2012","journal-title":"Cancer Res."},{"key":"2026082503243536800_B45","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1002\/cncr.25701","article-title":"Phase 1b-2a study to reverse platinum resistance through use of a hypomethylating agent, azacitidine, in patients with platinum-resistant or platinum-refractory epithelial ovarian cancer","volume":"117","author":"Fu","year":"2011","journal-title":"Cancer"},{"key":"2026082503243536800_B46","doi-asserted-by":"publisher","first-page":"S24","DOI":"10.1016\/S2352-5789(22)00262-4","article-title":"50 The role of DNA methyltransferase inhibitors (DNMTi) in the treatment of patients with recurrent epithelial ovarian cancer: a systematic review and meta-analysis","volume":"44","author":"Shafa","year":"2022","journal-title":"Gynecol. Oncol. Rep."},{"key":"2026082503243536800_B47","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s40661-017-0052-y","article-title":"EZH2 inhibition in ARID1A mutated clear cell and endometrioid ovarian and endometrioid endometrial cancers","volume":"4","author":"Alldredge","year":"2017","journal-title":"Gynecol. Oncol. Res. Pract."},{"key":"2026082503243536800_B48","doi-asserted-by":"publisher","first-page":"108473","DOI":"10.1016\/j.celrep.2020.108473","article-title":"Epigenomic reprogramming toward mesenchymal-epithelial transition in ovarian-cancer-associated mesenchymal stem cells drives metastasis","volume":"33","author":"Fan","year":"2020","journal-title":"Cell Rep."},{"key":"2026082503243536800_B49","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1038\/s41416-021-01321-0","article-title":"Achieving clinical success with BET inhibitors as anti-cancer agents","volume":"124","author":"Shorstova","year":"2021","journal-title":"Br. J. Cancer"},{"key":"2026082503243536800_B50","doi-asserted-by":"publisher","first-page":"106","DOI":"10.3892\/ol.2024.14852","article-title":"BET inhibitor JQ1 induces apoptosis of ovarian and endometrial endometrioid carcinoma cells by downregulating c-Myc","volume":"29","author":"Tanimoto","year":"2025","journal-title":"Oncol. Lett."},{"key":"2026082503243536800_B51","doi-asserted-by":"publisher","first-page":"3398","DOI":"10.1016\/j.celrep.2017.11.095","article-title":"BET bromodomain inhibition synergizes with PARP inhibitor in epithelial ovarian cancer","volume":"21","author":"Karakashev","year":"2017","journal-title":"Cell Rep."},{"key":"2026082503243536800_B52","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1186\/s13073-017-0500-7","article-title":"The potential of circulating tumor DNA methylation analysis for the early detection and management of ovarian cancer","volume":"9","author":"Widschwendter","year":"2017","journal-title":"Genome Med."},{"key":"2026082503243536800_B53","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1186\/s13148-020-00939-w","article-title":"Leveraging locus-specific epigenetic heterogeneity to improve the performance of blood-based DNA methylation biomarkers","volume":"12","author":"Miller","year":"2020","journal-title":"Clin. Epigenetics"},{"key":"2026082503243536800_B54","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.3390\/life12122017","article-title":"Search for new participants in the pathogenesis of high-grade serous ovarian cancer with the potential to be used as diagnostic molecules","volume":"12","author":"Timofeeva","year":"2022","journal-title":"Life (Basel)"},{"key":"2026082503243536800_B55","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.3390\/biomedicines9101316","article-title":"Role of circulating miRNAs in therapeutic response in epithelial ovarian cancer: a systematic revision","volume":"9","author":"Ravegnini","year":"2021","journal-title":"Biomedicines"},{"key":"2026082503243536800_B56","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.3390\/biomedicines9101433","article-title":"Circulating exosomal miRNAs as biomarkers in epithelial ovarian cancer","volume":"9","author":"Shiao","year":"2021","journal-title":"Biomedicines"},{"key":"2026082503243536800_B57","doi-asserted-by":"publisher","first-page":"88","DOI":"10.3390\/biology13020088","article-title":"Current applications and challenges of next-generation sequencing in plasma circulating tumour DNA of ovarian cancer","volume":"13","author":"Roque","year":"2024","journal-title":"Biology (Basel)"},{"key":"2026082503243536800_B58","doi-asserted-by":"publisher","first-page":"e0250717","DOI":"10.1371\/journal.pone.0250717","article-title":"In Silico screening of circulating tumor DNA, circulating microRNAs, and long non-coding RNAs as diagnostic molecular biomarkers in ovarian cancer: a comprehensive meta-analysis","volume":"16","author":"Zhang","year":"2021","journal-title":"PloS ONE"},{"key":"2026082503243536800_B59","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1093\/bfgp\/elz035","article-title":"Epigenome editing by CRISPR\/Cas9 in clinical settings: possibilities and challenges","volume":"19","author":"Pei","year":"2020","journal-title":"Brief Funct. Genomics"},{"key":"2026082503243536800_B60","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.ymeth.2020.04.006","article-title":"Targeting cancer epigenetics with CRISPR-dCAS9: principles and prospects","volume":"187","author":"Rahman","year":"2021","journal-title":"Methods"},{"key":"2026082503243536800_B61","doi-asserted-by":"publisher","first-page":"10","DOI":"10.31703\/gpsr.2024(IX-I).02","article-title":"Applications and challenges of CRISPER\/Cas-9 system in cancer therapy","volume":"9","author":"Masood","year":"2024","journal-title":"Global Pharmaceut. Sci. Rev."}],"container-title":["Bioscience Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/portlandpress.com\/bioscirep\/article-pdf\/doi\/10.1042\/BSR20250409\/991350\/bsr-2025-0409.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/portlandpress.com\/bioscirep\/article-pdf\/doi\/10.1042\/BSR20250409\/991350\/bsr-2025-0409.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T07:24:42Z","timestamp":1787642682000},"score":1,"resource":{"primary":{"URL":"https:\/\/portlandpress.com\/bioscirep\/article\/46\/9\/BSR20250409\/237970\/Epigenetic-mechanisms-and-clinical-translation-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,25]]},"references-count":61,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9,16]]}},"URL":"https:\/\/doi.org\/10.1042\/bsr20250409","relation":{},"ISSN":["0144-8463","1573-4935"],"issn-type":[{"value":"0144-8463","type":"print"},{"value":"1573-4935","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,9]]},"published":{"date-parts":[[2026,8,25]]},"article-number":"BSR20250409"}}